Endo International PLC

Endo International — Merger or Acquisition (May 2015)

35 slides from Endo International's merger presentation, May 18, 2015

  1. Slide 1: Par Pharmaceutical Acquisition

    Endo International plc Par Pharmaceutical Acquisition May 18, 2015 ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains information relating to the acquisition of Par by Endo that includes or is based on “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exc

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures This presentation may refer to non-GAAP financial measures, including EBITDA and adjusted gross margin, which are financial measures that are not prepared in conformity with accounting principles generally accepted in the United States (GAAP). We define adjusted gross mar

  4. Slide 4: Par Pharmaceutical Acquisition: Overview

    Par Pharmaceutical Acquisition: Overview Endo to acquire privately-held Par for $8.05 billion $1.55 billion in equity to Par shareholders $6.5 billion cash consideration Fully committed financing from Barclays and Deutsche Bank Expected to be financed by combination of cash, term loans, bonds and an

  5. Slide 5: Par Acquisition: Significant Value Creation

    Par Acquisition: Significant Value Creation • Diversifies product portfolio and R&D pipeline Capabilities • Expands manufacturing and technology capabilities Growth • Accretive to existing growth profile: expected to drive double-digit organic growth Profile • Revenue: double-digit CAGR for pro form

  6. Slide 6: Compelling Strategic & Financial Rationale

    Compelling Strategic & Financial Rationale Strategically expands product portfolio, R&D pipeline, capabilities and long-term growth drivers Adds extensive range of dosage forms and delivery systems Focus on specialized, market leading products Designed to accelerate Endo growth: Double-digit revenue

  7. Slide 7: Transaction Aligns with Endo's Strategic Direction

    Transaction Aligns with Endo’s Strategic Direction Build a leading global specialty pharmaceutical company Focus on maximizing the value of each of our core businesses Participate in specialty areas offering above average growth and favorable margins Transform operating model to maximize growth pote

  8. Slide 8: Endo's Execution of M&A Strategy Is Driving Value

    Endo’s Execution of M&A Strategy Is Driving Value Expanded Generics platform Expanded Generics platform Sharpened strategic focus on pharmaceuticals Branded Generics Int’l Boca Aug 2013 Sumavel DosePro Apr 2014 DAVA Jun 2014 AMS Divestiture Mar 2015 Q3 2015 close Par May 2015 2H 2015 close Paladin N

  9. Slide 9: Endo's Vision: Leading Specialty Pharmaceutical Co.

    Endo’s Vision: Leading Specialty Pharmaceutical Co. U.S. Branded U.S. Generics International Pharmaceuticals Transaction closed January 2015

  10. Slide 10: Generic Pharmaceuticals: Current Landscape

    Generic Pharmaceuticals: Current Landscape US Generic Pharma Market ($B) 120 100 80 60 40 20 0 2010A 2011A 2012A 2013A 2014A 2015P 2016P Substantial market opportunity for growth of generic products U.S. generics market growth expected to be driven by: Aging population Regulatory focus on increased

  11. Slide 11: Endo + Par: Creates a Top Generics Player

    Endo + Par: Creates a Top 5 Generics Player U.S. IMS Generics Sales ($ in billions) $10 $5 $0 [1] PF [2] GEP[3] Source: IMS Health LTM as of 10/31/14, Wall Street research. [1] Pro forma for acquisition of Par [2] Pro forma for acquisition of Ranbaxy [3] Pro form for acquisition of Hospira

  12. Slide 12: About Qualitest

    About Qualitest Founded in 1983 Acquired by Endo in 2010 Headquarters: Huntsville, AL Manufacturing Facilities: Huntsville, AL & Charlotte, NC 1,750 employees Double digit organic growth performance and outlook Strong volume growth across balanced portfolio of over 700 products Controlled substances

  13. Slide 13: About Par Pharmaceutical

    About Par Pharmaceutical Founded in 1978 Headquarters: Woodcliff Lake, NJ Manufacturing Facilities: NY/CT, MI, CA and India 2,000 employees Privately-held pharmaceutical company operating in the U.S. as two business segments: Generics : approx. 95 products with 215 pipeline programs Multiple dosage

  14. Slide 14: Endo + Par: Broad Facilities Footprint

    Endo + Par: Broad Facilities Footprint 2.7m sf footprint establishes leading generics player with capacity for additional growth Endo facility Par facility

  15. Slide 15: Par: Evolution from 2012 to Today

    Par: Evolution from 2012 to Today Revenue ($mm) Adj. Gross Profit Margin # of ANDAs on File Filed Market opportunity ($bn) # of Technologies $1,050 47% 85 $21bn $1,309 52% 115 $37bn

  16. Slide 16: Par Today: High-Value, Long-Term Growth Products

    Par Today: High-Value, Long-Term Growth Products Focus of core business is attractive high-value generics Paragraph IV, first-to-file and first-to-market opportunities Specialized products that are difficult to manufacture and/or present complex legal and regulatory challenges, including the generic

  17. Slide 17: Par Snapshot: Extended Release Products Leader

    Par Snapshot: Extended Release Products Leader Generics Extended Release (ER) market size: ~$10 billion1 Key market drivers: High barrier to entry Difficult to manufacture Par is one of the largest suppliers of ER products 13% generics ER market share for Par in 20141 In 2014, Par offered 6 of the t

  18. Slide 18: Par Snapshot: Injectables Products Driving Growth

    Par Snapshot: Injectables Products Driving Growth Generics injectables market size: ~$20 billion1 Key market drivers: Difficult to manufacture High regulatory scrutiny Par injectables capabilities rapidly expanding; goal to be leading generic injectables provider within 3-5 years Par entered the mar

  19. Slide 19: Par R&D Strategy: Building a High-Value Pipeline

    Par R&D Strategy: Building a High-Value Pipeline Par has a full suite of high-value, high barrier to entry product technologies in development, including: ER oral solids Injectables Topicals Nasal sprays Ophthalmics Films ~60% of filed ANDAs (115 total) are alternative dosage forms ~70% of R&D pipel

  20. Slide 20: Endo + Par: Expanded Internal Generics R&D Capabilities

    Endo + Par: Expanded Internal Generics R&D Capabilities… Technology Dev. Programs Oral Pre- Cont-Oral Topical Nasal Ophth- Sterile Solid filled Patch Film API rolled NDA ANDA CRO Solid IR / Liquid Sprays almics Vials ER Syringe Subs + Capability development in process ©2015 Endo Pharmaceuticals Inc.

  21. Slide 21: Endo + Par: Drive a Diversified R&D Engine

    Endo + Par: …Drive a Diversified R&D Engine Endo Filed ANDAs (50) Par Filed ANDAs (115) 14% 6% 28% 6% 10% 0 18% 0 0 18% 18% 42% 11% 29% Immediate Release Extended Release Injectables Topical Sprays/Nasal/Subling Ophthal Film Other SoftGel O C’s Liquids ©2015 Endo Pharmaceuticals Inc. All rights rese

  22. Slide 22: Endo + Par: Drive a Diversified R&D Engine

    Endo + Par: …Drive a Diversified R&D Engine Endo Pro Forma Filed ANDAs (165) Liquids OCs Topicals 2% 4% Soft Gels 5% 0 0 2% Immediate 0% Release 38% 16% Other 8% Injectables 25% Extended Release ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  23. Slide 23: Endo + Par: Drive a Diversified R&D Engine

    Endo + Par: …Drive a Diversified R&D Engine Endo Programs in Development (52) Par Programs in Development (100) >75% of Par Development programs are Paragraph IV / First-to-File 10% 4% 0 6% 6% 50% 2% 6% 17% 2% 5% 5% 3% 27% 9% 25% 24% ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  24. Slide 24: Endo + Par: Drive a Diversified R&D Engine

    Endo + Par: …Drive a Diversified R&D Engine Endo Pro Forma Programs in Development (152) Liquids Topicals 3% Soft Gels 8% 1%Films 1% 1% Ophthalmic Release Sprays / 5% Nasal / 35% 3% Sublingual Other 5% 16% Injectables 22% Extended Release HALF of all Development programs are Paragraph IV / First-to-

  25. Slide 25: Endo + Par: Significant Generics Growth Potential

    Endo + Par: Significant Generics Growth Potential Net Revenues ($000s) Pro Forma $2,500 $2,000 $1,500 $1,000 $500 $0 2011 2012 2013 2014 Par Endo (Gx Only) Adjusted Gross Margin ($000s) Pro Forma $1,400 49% $1,200 $1,000 $800 47% $600 $400 $200 $0 2011 2012 2013 2014 Par Endo (Gx Only) Adj Gross Mar

  26. Slide 26: Financing Structure Provides Flexibility for Future M&A

    Summary: Financing Structure Provides Flexibility for Future M&A Attractive de-levering profile Strong cash flow leads to rapid de-levering Expect to be back in the 3-4x net debt to EBIDTA range in 12-18 months $8.05 Billion Transaction $1.55 Billion Equity $6.50 Billion Cash Consideration Considera

  27. Slide 27: Par Acquisition: Significant Value Creation

    Par Acquisition: Significant Value Creation Capabilities Diversifies product portfolio and R&D pipeline Expands manufacturing and technology capabilities Accretive to existing growth profile: expected to drive double-digit Growth organic growth Profile Revenue: double-digit CAGR for pro forma revenu

  28. Slide 28: Endo + Par: A Leading Specialty Pharmaceutical Co.

    Summary: Endo + Par: A Leading Specialty Pharmaceutical Co. Spec Pharma Landscape by Enterprise Value ($ in billions) $100 $167 $103 $75 $62 $54 $50 $44 $33 $28 $25 $20 $12 $9 $8 $6 $0 PF Source: FactSet. Note: Market data as of 5/15/15.

  29. Slide 29: Endo + Par: A Transformational Combination

    Summary: Endo + Par: A Transformational Combination Company Size and Scale Generics (2014) Generics R&D Pipeline Long Term Growth Drivers Enterprise Value: ~$20bn 2014 Revenue: ~$2.9bn 2014 Revenue: ~$1.1bn (+56% from 2013) ~90 programs 6 ANDAs to be filed in 2015 Expansion of branded and generic po

  30. Slide 30: Appendix

    Appendix ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  31. Slide 31: Reconciliation of Par Non-GAAP Measures - EBITDA

    Reconciliation of Par Non-GAAP Measures - EBITDA ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  32. Slide 32: Reconciliation of Par Non-GAAP Measures – EBITDA (continued)

    Reconciliation of Par Non-GAAP Measures – EBITDA (continued) ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  33. Slide 33: Reconciliation of Par Non-GAAP Measures – Gross Margin

    Reconciliation of Par Non-GAAP Measures – Gross Margin ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  34. Slide 34: Reconciliation of Endo (Gx Only) Non-GAAP Measures – Gross Margin

    Reconciliation of Endo (Gx Only) Non-GAAP Measures – Gross Margin We define adjusted gross margin as total revenues, less cost of revenues, adjusted for amortization of intangible assets; certain upfront and milestone payments to partners; certain cost reduction and integration-related initiatives;

  35. Slide 35: Endo International plc

    Endo International plc Par Acquisition May 18, 2015 ©2015 Endo Pharmaceuticals Inc. All rights reserved.

Endo International — Merger or Acquisition (May 2015) on 6ix